Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
neoR-TORCH: SBRT + Toripalimab + Chemotherapy in Resectable Stage II-III NSCLC
NCT06437977Phase 3Recruiting
- Sponsor
- Shanghai Chest Hospital
- Start
- Sep 2024
- Primary completion
- Jun 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of toripalimab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Shanghai Chest Hospital. Primary endpoints: 2-year Event Free Survival Rate and Pathological Complete Response rate. Started Sep 2024; status: recruiting.
02
Drugs
toripalimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06437977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06437977.